Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASND NYSEARCA:DBV NYSE:NBY NYSE:RTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$169.90-4.1%$169.61$111.09▼$183.00$10.39B0.38507,078 shs617,646 shsDBVInvesco DB G10 Currency Harvest Fund$25.41$25.41$24.25▼$28.40$25.41M0.2327,852 shsN/ANBYNovaBay Pharmaceuticals$0.66+2.0%$0.60$0.36▼$2.26$3.86M0.44117,507 shs15,680 shsRTIRTI International Metals$0.00$0.00▼$0.00N/AN/AN/AN/AInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S-4.12%-2.89%-0.47%+2.94%+22.61%DBVInvesco DB G10 Currency Harvest Fund0.00%0.00%0.00%0.00%0.00%NBYNovaBay Pharmaceuticals+2.00%-4.19%+8.67%+10.50%-67.97%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S3.616 of 5 stars4.53.00.00.02.81.70.6DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/AN/AN/ANBYNovaBay Pharmaceuticals1.6371 of 5 stars3.50.00.00.00.60.01.3RTIRTI International MetalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$223.0731.29% UpsideDBVInvesco DB G10 Currency Harvest Fund 0.00N/AN/AN/ANBYNovaBay Pharmaceuticals 3.00Buy$0.8528.21% UpsideRTIRTI International Metals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RTI, ASND, NBY, and DBV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025ASNDAscendis Pharma A/SCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$213.00 ➝ $243.007/3/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$250.006/13/2025ASNDAscendis Pharma A/SOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$215.00 ➝ $224.006/9/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$201.00 ➝ $216.006/3/2025ASNDAscendis Pharma A/SBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$196.00 ➝ $201.005/12/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.005/5/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.005/2/2025ASNDAscendis Pharma A/SRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.005/2/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.005/2/2025ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$181.00 ➝ $212.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$393.54M26.39N/AN/A($1.88) per share-90.37DBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/AN/ANBYNovaBay Pharmaceuticals$9.78M0.39N/AN/A$4.25 per share0.16RTIRTI International MetalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$6.28N/A707.92N/A-93.22%N/A-33.29%9/2/2025 (Estimated)DBVInvesco DB G10 Currency Harvest FundN/AN/A0.00∞N/AN/AN/AN/AN/ANBYNovaBay Pharmaceuticals-$9.64M-$53.72N/AN/AN/A-102.72%-7,293.78%-158.41%N/ARTIRTI International MetalsN/AN/A0.00N/AN/AN/AN/AN/AN/ALatest RTI, ASND, NBY, and DBV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ADBVInvesco DB G10 Currency Harvest FundN/AN/AN/AN/AN/ANBYNovaBay PharmaceuticalsN/AN/AN/AN/AN/ARTIRTI International MetalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.040.71DBVInvesco DB G10 Currency Harvest FundN/AN/AN/ANBYNovaBay PharmaceuticalsN/A1.150.91RTIRTI International MetalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ADBVInvesco DB G10 Currency Harvest Fund85.24%NBYNovaBay Pharmaceuticals23.25%RTIRTI International MetalsN/AInsider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%DBVInvesco DB G10 Currency Harvest FundN/ANBYNovaBay Pharmaceuticals0.10%RTIRTI International MetalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S1,01761.13 million36.68 millionOptionableDBVInvesco DB G10 Currency Harvest Fund801.00 millionN/ANot OptionableNBYNovaBay Pharmaceuticals305.82 million4.88 millionNot OptionableRTIRTI International MetalsN/AN/AN/ANot OptionableRTI, ASND, NBY, and DBV HeadlinesRecent News About These CompaniesRTI International CEO on drastic funding cuts and his NC nonprofit’s market pivotJune 27, 2025 | msn.comLightstorm finishes integrating subsea cables bought from RTIMay 9, 2025 | datacenterdynamics.comDRTI INTERNATIONAL METALS (NYSE: RTI) - Share Price and ResearchMay 6, 2025 | intelligentinvestor.com.auIRTI International layoffs expected to reach at least 525 by May 1, organization saysMarch 27, 2025 | wral.comWRTI International layoff expected to reach at least 525 by May 1, organization saysMarch 27, 2025 | msn.comOpen Source: RTI International CEO makes seven figures. Does that justify USAID cuts?February 21, 2025 | msn.comRTI International to temporarily lay off staff due to US foreign aid freezeFebruary 14, 2025 | wunc.orgWRTI International lays off US workers, including in NC, citing Trump’s USAID cutsFebruary 13, 2025 | msn.comRTI International layoffs hit NC due to US freeze on foreign aidFebruary 13, 2025 | wral.comWResearch Urges Tyre Particles as Unique Eco ThreatNovember 14, 2024 | miragenews.comMA digital exam reels in engraved scenes of Stone Age net fishingNovember 7, 2024 | sciencenews.orgSRussia explores creation of international precious metals exchangeOctober 26, 2024 | msn.comRussia in talks with BRICS over precious metals exchangeOctober 24, 2024 | reuters.comRTI Joins the Common Vulnerabilities and Exposures (CVE®) Program as a CVE Numbering Authority (CNA)October 22, 2024 | markets.businessinsider.comRTI Awarded Elite Supplier Status by Lockheed Martin's Rotary and Mission Systems (RMS) DivisionOctober 15, 2024 | tmcnet.comAnalysts Conflicted on These Materials Names: Coeur Mining (CDE), RPM International (RPM) and Rio Tinto Limited (OtherRTNTF)October 10, 2024 | markets.businessinsider.comEnergy transition story rekindles fund interest in metalsOctober 7, 2024 | reuters.comJai Bhim Nagar Demolition: Mumbai Police To File FIR Against BMC Officers And PolicemenOctober 4, 2024 | msn.comRTI International Teams Up with USAID, UNICEF to Create a Lead-Free FutureOctober 4, 2024 | morningstar.comMMumbai: BMC Reveals Construction Of Two-Level Underground Parking Lot At Breach Candy In Response To RTI Amid Resident ConcernsOctober 3, 2024 | freepressjournal.inFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseWhat to Expect From the Q2 Earnings Reporting CycleBy Thomas Hughes | June 23, 2025View What to Expect From the Q2 Earnings Reporting CycleThe Meteoric Rise of Rocket Lab: A Space Stock to WatchBy Ryan Hasson | July 11, 2025View The Meteoric Rise of Rocket Lab: A Space Stock to Watch3 High-Risk, High-Reward Stocks With Explosive UpsideBy Nathan Reiff | July 16, 2025View 3 High-Risk, High-Reward Stocks With Explosive UpsideRTI, ASND, NBY, and DBV Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$169.90 -7.30 (-4.12%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$171.00 +1.10 (+0.65%) As of 07/18/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Invesco DB G10 Currency Harvest Fund NYSEARCA:DBV$25.41 0.00 (0.00%) As of 03/10/2023PowerShares DB G10 Currency Harvest Fund (the Fund) is an index tracking fund and does not utilize any trading system, whether discretionary, systematic or otherwise. The Fund offers common units of beneficial interest (the Shares) only to certain eligible financial institutions (the Authorized Participants) in one or more blocks of 200,000 Shares, called a Basket. The Index is designed to reflect the return from investing on a 2:1 leveraged basis in long currency futures positions for certain currencies associated with relatively high yielding interest rates and in short currency futures positions for certain currencies associated with relatively low yielding interest rates. DB Commodity Services LLC serves as the managing owner, commodity pool operator and commodity trading advisor of the Fund.NovaBay Pharmaceuticals NYSE:NBY$0.66 +0.01 (+2.00%) As of 07/18/2025 04:00 PM EasternNovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.RTI International Metals NYSE:RTIRTI International Metals, Inc. is a producer and global supplier of titanium mill products and a manufacturer of fabricated titanium and specialty metal components for the national and international aerospace, defense, energy, medical device, and other consumer and industrial markets. The Company operates in two segments: the Titanium segment and Engineered Products and Services (EP&S) segment. The Titanium Segment melts, processes, produces, forges, stocks, distributes, finishes, cuts-to-size, and facilitates just-in-time delivery services of a complete range of titanium mill products, which are further processed by its customers for use in a variety of commercial aerospace, defense, and industrial and consumer applications. The EP&S Segment is comprised of companies with significant hard and soft-metal expertise that form, extrude, fabricate, machine, additively manufacture, micro-machine, and assemble titanium, aluminum, and other specialty metal parts and components. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
